Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines

Kenichi Harada, Shinichi Toyooka, Anirban Maitra, Riichiroh Maruyama, Kiyomi O. Toyooka, Charles F. Timmons, Gail E. Tomlinson, Domenico Mastrangelo, Robert J. Hay, John D. Minna, Adi F. Gazdar

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16INK4A, MGMT, GSTP1, RASSF1A, APC, DAPK, RARβ, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86%, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88%. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and non-malignant tissues (less than 5%). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P = 0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2′deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.

Original languageEnglish (US)
Pages (from-to)4345-4349
Number of pages5
JournalOncogene
Volume21
Issue number27
DOIs
StatePublished - Jun 20 2002

Fingerprint

Gene Silencing
Tumor Cell Line
Methylation
Pediatrics
Neoplasms
Neuroblastoma
p16 Genes
Hepatoblastoma
Cell Line
Polymerase Chain Reaction
Messenger RNA
Medulloblastoma
Ewing's Sarcoma
Wilms Tumor
Rhabdomyosarcoma
Retinoblastoma
Osteosarcoma
Tumor Suppressor Genes
Genes
Leukemia

Keywords

  • Epigenetic
  • Pediatric tumor
  • Tumor suppressor gene

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Harada, K., Toyooka, S., Maitra, A., Maruyama, R., Toyooka, K. O., Timmons, C. F., ... Gazdar, A. F. (2002). Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene, 21(27), 4345-4349. https://doi.org/10.1038/sj.onc.1205446

Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. / Harada, Kenichi; Toyooka, Shinichi; Maitra, Anirban; Maruyama, Riichiroh; Toyooka, Kiyomi O.; Timmons, Charles F.; Tomlinson, Gail E.; Mastrangelo, Domenico; Hay, Robert J.; Minna, John D.; Gazdar, Adi F.

In: Oncogene, Vol. 21, No. 27, 20.06.2002, p. 4345-4349.

Research output: Contribution to journalArticle

Harada, K, Toyooka, S, Maitra, A, Maruyama, R, Toyooka, KO, Timmons, CF, Tomlinson, GE, Mastrangelo, D, Hay, RJ, Minna, JD & Gazdar, AF 2002, 'Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines', Oncogene, vol. 21, no. 27, pp. 4345-4349. https://doi.org/10.1038/sj.onc.1205446
Harada, Kenichi ; Toyooka, Shinichi ; Maitra, Anirban ; Maruyama, Riichiroh ; Toyooka, Kiyomi O. ; Timmons, Charles F. ; Tomlinson, Gail E. ; Mastrangelo, Domenico ; Hay, Robert J. ; Minna, John D. ; Gazdar, Adi F. / Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. In: Oncogene. 2002 ; Vol. 21, No. 27. pp. 4345-4349.
@article{0cf891e30a734cbe90a462d8db7684f8,
title = "Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines",
abstract = "Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16INK4A, MGMT, GSTP1, RASSF1A, APC, DAPK, RARβ, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86{\%}, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88{\%}. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and non-malignant tissues (less than 5{\%}). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P = 0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2′deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.",
keywords = "Epigenetic, Pediatric tumor, Tumor suppressor gene",
author = "Kenichi Harada and Shinichi Toyooka and Anirban Maitra and Riichiroh Maruyama and Toyooka, {Kiyomi O.} and Timmons, {Charles F.} and Tomlinson, {Gail E.} and Domenico Mastrangelo and Hay, {Robert J.} and Minna, {John D.} and Gazdar, {Adi F.}",
year = "2002",
month = "6",
day = "20",
doi = "10.1038/sj.onc.1205446",
language = "English (US)",
volume = "21",
pages = "4345--4349",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "27",

}

TY - JOUR

T1 - Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines

AU - Harada, Kenichi

AU - Toyooka, Shinichi

AU - Maitra, Anirban

AU - Maruyama, Riichiroh

AU - Toyooka, Kiyomi O.

AU - Timmons, Charles F.

AU - Tomlinson, Gail E.

AU - Mastrangelo, Domenico

AU - Hay, Robert J.

AU - Minna, John D.

AU - Gazdar, Adi F.

PY - 2002/6/20

Y1 - 2002/6/20

N2 - Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16INK4A, MGMT, GSTP1, RASSF1A, APC, DAPK, RARβ, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86%, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88%. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and non-malignant tissues (less than 5%). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P = 0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2′deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.

AB - Aberrant promoter methylation of tumor suppressor genes has not been fully investigated in pediatric tumors. Therefore, we examined the methylation status of nine genes (p16INK4A, MGMT, GSTP1, RASSF1A, APC, DAPK, RARβ, CDH1 and CDH13) in 175 primary pediatric tumors and 23 tumor cell lines using methylation-specific PCR. We studied the major forms of pediatric tumors - Wilms' tumor, neuroblastoma, hepatoblastoma, medulloblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, retinoblastoma and acute leukemia. The most frequently methylated gene in both primary tumors and cell lines was RASSF1A (40, 86%, respectively). However, the rates of RASSF1A methylation in individual tumor types varied from 0 to 88%. RASSF1A methylation was tumor specific and was absent in adjacent non-malignant tissues. Methylation of the other genes was relatively rare in tumors and non-malignant tissues (less than 5%). Neuroblastoma patients with methylation of RASSF1A were significantly older than patients without methylation (P = 0.008). There was no relationship between methylation status and other clinico-pathologic parameters. We treated six cell lines lacking RASSF1A mRNA with 5-aza-2′deoxycytidine to examine the relationship between methylation and transcriptional silencing. In five of six cell lines, restoration of RASSF1A mRNA was confirmed by RT-PCR. Our findings indicate that aberrant promoter methylation of RASSF1A may contribute to the pathogenesis of many different forms of pediatric tumors.

KW - Epigenetic

KW - Pediatric tumor

KW - Tumor suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=18444379044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18444379044&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1205446

DO - 10.1038/sj.onc.1205446

M3 - Article

C2 - 12082624

AN - SCOPUS:18444379044

VL - 21

SP - 4345

EP - 4349

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 27

ER -